Yıl: 2022 Cilt: 44 Sayı: 1 Sayfa Aralığı: 1 - 12 Metin Dili: İngilizce DOI: 10.20515/otd.943501 İndeks Tarihi: 07-09-2022

Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices

Öz:
The aim of this study is to identify the factors affecting mortality in patients with chronic obstructive pulmonary disease (COPD) hospitalized with exacerbation. A COPD cohort study was designed. Demographic data, the reason of mortality, Charlson co-morbidity index (CCI), COPD comorbidity index (COTE), age, dyspnea, airway obstruction (ADO) index, modified ADO index and dyspnea, airway obstruction, smoking, exacerbation (DOSE) index, and their relationship with mortality were investigated. One hundred and forty COPD patients hospitalized with exacerbation were included in the study. Eighty-seven (62.15%) of the patients were alive and 53 (37.85%) of them were deceased. The number of patients with CCI ≥ 7 was none in living patients and 11 (20.8%) in the deceased group (p<0.001). The percentage of treatment compliant patients during stable conditions was lower in the deceased group (p<0.001). ADO and COTE indices were significantly higher in the deceased group. There was no difference in modified ADO and DOSE scores between the groups. Multivariate analysis showed that lung cancer, CCI 7, hypoxemia (PaO2 <60 mmHg), and longer admission to the intensive care unit were independently associated with 3.4, 4.4, 2.1, and 3.0-fold mortality, respectively (p <0.05). Additionally, COTE ≥ 4 and noncompliance to regular COPD treatment were found to be associated with shorter survival in Kaplan Meier analysis (p<0.05). In conclusion, comorbidities and most notably lung cancer was associated with mortality in COPD. Also, high CCI and COTE index were risk factors for increased mortality.
Anahtar Kelime: COPD mortality ADO DOSE COTE CCI

Hastanede Kronik Obstrüktif Akciğer Hastalığı Ataklarında Uzun Dönem Mortalite: Çoklu İndekslerin Karşılaştırılması

Öz:
Bu çalışmada amaç kronik obstrüktif akciğer hastalığı (KOAH) alevlenmesi ile hastaneye yatırılan olan hastalarda mortaliteyi etkileyen faktörleri belirlemektir. Bir KOAH kohort çalışması tasarlanmıştır. Demografik veriler, mortalite nedeni, Charlson komorbidite indeksi (CCI), KOAH komorbidite indeksi (COTE), yaş, dispne, hava yolu tıkanma (ADO) indeksi, modifiye ADO indeksi ve dispne, hava yolu tıkanması, sigara, alevlenme (DOSE) indeksi ve bunların mortalite ile ilişkisi araştırıldı. Çalışmaya KOAH alevlenmesi ile yatan 140 KOAH hastası dahil edildi. Hastaların 87'si (%62.15) hayatta iken 53'ü (%37.85) ölmüştü. Yaşayan hastalarda CCI ≥ 7 olan hasta yokken, ölen grupta 11 (%20.8) kişide CCI ≥ 7 idi (p <0.001). Stabil durumda tedaviye uyumlu hasta yüzdesi ölen grupta daha düşüktü (p <0.001). Değiştirilmiş ADO indeks yüzdesi ölen grupta daha düşüktü (p <0.001). Ölen grupta ADO ve COTE indeksleri anlamlı olarak daha yüksekti. Gruplar arasında modifiye ADO ve DOSE skorlarında fark yoktu. Çok değişkenli analiz, akciğer kanseri, CCI ≥ 7, hipoksemi (PaO2 <60 mmHg) ve yoğun bakım ünitesine daha uzun başvuru almasının sırasıyla 3.4, 4.4, 2.1 ve 3.0 kat mortalite ile bağımsız olarak ilişkili olduğunu gösterdi (p < 0.05). Ek olarak, Kaplan Meier analizinde COTE ≥ 4 ve düzenli KOAH tedavisine uyumsuzluğun daha kısa sağkalım ile ilişkili olduğu bulunmuştur (p <0.05). Sonuç olarak, komorbiditeler ve en belirgin olarak akciğer kanseri, KOAH'da mortalite ile ilişkili bulunmuştur. Aynı zamanda yüksek CCI ve COTE indeksleri de mortalite ile ilişkilidir.
Anahtar Kelime: KOAH mortalite ADO DOSE COTE CCI

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990– 2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Respir Med. 2017; 5: 691.
  • 2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012; 380: 2095-128.
  • 3. Cote CG. Surrogates of mortality in chronic obstructive pulmonary disease. Am J Med. 2006; 119(10): 54-62.
  • 4. Celli BR. Predictors of mortality in COPD. Respir Med. 2010; 104: 773-9.
  • 5. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez PR, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease: Thorax 2005; 60: 925–31.
  • 6. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017; 195: 557-82.
  • 7. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 871.
  • 8. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-83.
  • 9. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186: 155-61.
  • 10. Celli BR, Cote CG, Marin JM, et al. The body- mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12.
  • 11. Almagro P, Soriano JB, Cabrera FJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014; 145: 972-80.
  • 12. Halpin DM, Criner GJ, Papi A, et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021; 203: 24-36.
  • 13. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005; 26: 153-61.
  • 14. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106: 196-204.
  • 15. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ. 1960; 2: 1665.
  • 16. van der Bruggen-Bogaarts BA, van der Bruggen HM, van Waes PF, et al. Assessment of bronchiectasis: comparison of HRCT and spiral volumetric CT. J Comput Assist Tomogr. 1996; 20: 15-9.
  • 17. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. The Lancet. 2009; 374: 704-11.
  • 18. Puhan MA, Hansel NN, Sobradillo P, et al. Large- scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ open. 2012; 2(6).
  • 19. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009; 180: 1189-95.
  • 20. Patil SP, Krishnan JA, Lechtzin N, et al. In- hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003; 163: 1180-6.
  • 21. Afessa B, Morales IJ, Scanlon PD, et al. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med. 2002; 30: 1610-5.
  • 22. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274: 1852-7.
  • 23. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67: 957-63.
  • 24. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005; 26: 234-41.
  • 25. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142: 233-9.
  • 26. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007; 62: 411-5.
  • 27. McGarvey LP, Magder S, Burkhart D, et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med. 2012; 106: 515-21.
  • 28. Putcha N, Drummond MB, Wise RA, et al. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015; 36: 575-91.
  • 29. Prudente R, Franco EA, Mesquita CB, et al. Predictors of mortality in patients with COPD after 9 years. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3389.
APA sari g, Kilic H, Yılmaz Ş, demir baha a, UĞRAŞ DİKMEN A, Kokturk N (2022). Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. , 1 - 12. 10.20515/otd.943501
Chicago sari gulcin,Kilic Hatice,Yılmaz Şenay,demir baha ayse,UĞRAŞ DİKMEN ASİYE,Kokturk Nurdan Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. (2022): 1 - 12. 10.20515/otd.943501
MLA sari gulcin,Kilic Hatice,Yılmaz Şenay,demir baha ayse,UĞRAŞ DİKMEN ASİYE,Kokturk Nurdan Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. , 2022, ss.1 - 12. 10.20515/otd.943501
AMA sari g,Kilic H,Yılmaz Ş,demir baha a,UĞRAŞ DİKMEN A,Kokturk N Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. . 2022; 1 - 12. 10.20515/otd.943501
Vancouver sari g,Kilic H,Yılmaz Ş,demir baha a,UĞRAŞ DİKMEN A,Kokturk N Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. . 2022; 1 - 12. 10.20515/otd.943501
IEEE sari g,Kilic H,Yılmaz Ş,demir baha a,UĞRAŞ DİKMEN A,Kokturk N "Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices." , ss.1 - 12, 2022. 10.20515/otd.943501
ISNAD sari, gulcin vd. "Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices". (2022), 1-12. https://doi.org/10.20515/otd.943501
APA sari g, Kilic H, Yılmaz Ş, demir baha a, UĞRAŞ DİKMEN A, Kokturk N (2022). Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. Osmangazi Tıp Dergisi, 44(1), 1 - 12. 10.20515/otd.943501
Chicago sari gulcin,Kilic Hatice,Yılmaz Şenay,demir baha ayse,UĞRAŞ DİKMEN ASİYE,Kokturk Nurdan Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. Osmangazi Tıp Dergisi 44, no.1 (2022): 1 - 12. 10.20515/otd.943501
MLA sari gulcin,Kilic Hatice,Yılmaz Şenay,demir baha ayse,UĞRAŞ DİKMEN ASİYE,Kokturk Nurdan Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. Osmangazi Tıp Dergisi, vol.44, no.1, 2022, ss.1 - 12. 10.20515/otd.943501
AMA sari g,Kilic H,Yılmaz Ş,demir baha a,UĞRAŞ DİKMEN A,Kokturk N Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. Osmangazi Tıp Dergisi. 2022; 44(1): 1 - 12. 10.20515/otd.943501
Vancouver sari g,Kilic H,Yılmaz Ş,demir baha a,UĞRAŞ DİKMEN A,Kokturk N Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices. Osmangazi Tıp Dergisi. 2022; 44(1): 1 - 12. 10.20515/otd.943501
IEEE sari g,Kilic H,Yılmaz Ş,demir baha a,UĞRAŞ DİKMEN A,Kokturk N "Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices." Osmangazi Tıp Dergisi, 44, ss.1 - 12, 2022. 10.20515/otd.943501
ISNAD sari, gulcin vd. "Long Term Mortality in Hospitalized Chronic Obstructive Pulmonary Disease Exacerbation: A Comparison of Multiple Indices". Osmangazi Tıp Dergisi 44/1 (2022), 1-12. https://doi.org/10.20515/otd.943501